参考文献: 1.Tatyana Shamanskaya,et al. Tolerance and Toxicity of Induction Chemoimmunotherapy with Dinutuximab Beta in Newly Diagnosed Patients with High-Risk Neuroblastoma. SIOP 2024. Abstract ID: 770. 2. Xuedi Yu,...
doi:10.1002/1096-911X(200009)35:3<267::AID-MPO13>3.0.CO;2-ACoppes-ZantingaDepartments of Oncology and Pediatrics, Faculty of Medicine, University of Calgary, and the Tom Baker Cancer Center (Alberta Cancer Board), Calgary, Alberta, Canada.Coppes...
1.Tatyana Shamanskaya,et al. Tolerance and Toxicity of Induction Chemoimmunotherapy with Dinutuximab Beta in Newly Diagnosed Patients with High-Risk Neuroblastoma. SIOP 2024. Abstract ID: 770. 2. Xuedi Yu,et al. A Clinical Observational Study of Dinutuximab Beta as First-Line MaintenanceTreatm...
拉罗替尼开启儿童实体瘤治疗新征程,疗效及安全性独特 2023 SIOP大会分别公布了一项拉罗替尼在儿童TRK融合肿瘤患者(Abstract 339)和一项拉罗替尼在局部晚期或转移性婴儿纤维肉瘤(IFS)儿童患者(Abstract 193)中的研究,拉罗替尼均表现出优异的疗效和良好的安全性。 拉罗替尼治疗儿童TRK融合肿瘤疗效和安全性的长期随访[3]...
Previous Presentation of an Abstract– the work must not have been previously presented at a meeting of any other scientific organization with more than 500 attendees prior to the SIOP congress LIMITATIONS Prospective multicenter trials as well as presentation of large translational works are considered...
Previous Presentation of an Abstract– the work must not have been previously presented at a meeting of any other scientific organization with more than 500 attendees prior to the SIOP congress LIMITATIONS Prospective multicenter trials as well as presentation of large translational works are considered...
Abstract SIOP 2018: Biomolecular Analysis of Pediatric Medulloblastoma and Prognostic Relevance of FSTL5 Expression: A Single-Center Study Biomolecular Analysis of Pediatric Medulloblastoma and Prognostic Relevance of FSTL5 Expression: A Single-Center Study Aim: We retrospectively evaluated th......
5. Mascarenhas L, et al. Poster presentation at ASCO 2022; Abstract 10030. 6. DuBois SG, et al. Cancer. 2018;124:4241–4247. 7. Laetsch TW, et al. J Clin Oncol 2017;35(15 Suppl):Abstract 10510. Presentation at ASCO...
5. Mascarenhas L, et al. Poster presentation at ASCO 2022; Abstract 10030. 6. DuBois SG, et al. Cancer. 2018;124:4241–4247. 7. Laetsch TW, et al. J Clin Oncol 2017;35(15 Suppl):Abstract 10510. Presentation at ASCO 2017.
Hepatopathy-thrombocytopenia syndrome (HTS) in a child while receiving actinomycin-d therapy for wilms tumor (WT). Pediatric Blood and Cancer 60 (Suppl. S3): 232-233, Sep 2013. Available from: URL: http://dx..org/10.1002/pbc.24719 [abstract] - Turkey...